An­oth­er AD­HD fail­ure ce­ments Ae­vi's pen­ny stock sta­tus

Ae­vi Ge­nom­ic Med­i­cine’s ge­net­ic ap­proach to treat­ing AD­HD was ex­pect­ed to as­cend its lead drug to great heights in the com­mon­ly di­ag­nosed neu­robe­hav­ioral dis­or­der, but this saga has on­ly cul­mi­nat­ed in an­oth­er tri­al fail­ure, forc­ing the re­source-poor com­pa­ny to “re­duce the scope” of its op­er­a­tions to pre­serve cap­i­tal.

Shares of the Philadel­phia-based com­pa­ny $GN­MX were oblit­er­at­ed Wednes­day af­ter­noon, nose­div­ing near­ly 65% af­ter the bell, wad­ing deep­er in­to pen­ny stock ter­ri­to­ry.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.